<DOC>
	<DOC>NCT02539654</DOC>
	<brief_summary>The purpose of this study is to describe the pharmacokinetics (PK) of EXE844 Sterile Otic Suspension, 0.3% following a single bilateral ototopical dose in pediatric subjects, immediately after bilateral tympanostomy tube surgery.</brief_summary>
	<brief_title>Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<criteria>Recurrent acute otitis media (RAOM) or chronic otitis media with effusion (COME) and eligible for bilateral myringotomy and tympanostomy tube insertion; Legally Authorized Representative (LAR) must read and sign the informed consent; Parent or caregiver must agree to complete the required study visits and comply with the requirements of the study; Other protocolspecified inclusion criteria amy apply. Menarcheal females; Previous otologic or otologicrelated surgery within the past 30 days or ongoing complications; Existing perforation of the eardrum; Current acute otitis externa (AOE), malignant otitis externa (MOE) or other conditions which could interfere with evaluation of the study drug; Any systemic disease or disorder, complicating factor or structural abnormality that would negatively affect the conduct or outcome of the study; Use of prohibited medications or inadequate washout of any medication including systemic and topical antibiotics, steroids and/or analgesics; Weighs less than 8 kg; Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>